More specifically we found no significant changes in peptides belonging to known validated cancer antigens such as survivin [55], NY-ESO [56] or melanoma-associated antigen protein family genes (MAGEs) [57] that could have partially explained the increased immunogenicity, previously observed upon HOCl antigen treatment [16]. Here, BIRC5 is linked to cancer.